PMC7242611_01
Graphical representation of the clinical course and therapeutic procedures. Above: Different pharmacological strategies. Below: Symptom course.
fpsyt-11-00245-g001.jpg
PMC7242611_01_fpsyt-11-00245-g001.jpg
f1
In summary, initial anti-inflammatory therapy (glucocorticoids, plasmapheresis, azathioprine, MMF) as well as later low-dose neuroleptics (risperidone, amisulpride) and CBT had a remarkable impact on symptom relief (Figure 1). Overall, there was an increase in IRDA rates (Figure 3 and Table 1).
Initial (2010, at the top) and follow-up (2019, at the bottom) magnet resonance imaging findings with combined volume- and region-based analysis method (CVR) revealed an enlargement of the lateral ventricles with emphasis on the posterior horns and slight striatal and insular atrophy. There was no relevant change in findings between 2010 and 2019 ().
fpsyt-11-00245-g002.jpg
PMC7242611_01_fpsyt-11-00245-g002.jpg
f2
The automated analysis of the structural MRI revealed an enlargement of the lateral ventricles with emphasis on the posterior horns and slight striatal and insular atrophy (Figure 2).
Electroencephalography (EEG) analysis using independent component analysis (ICA, left) and intermittent rhythmic delta activity (IRDA) rates (right). The follow-up EEG analysis in 2019 showed strong alpha-activity and some IRDAs in component 4 and 8 (left). The left-temporal component (8) contains individual spike wave complexes. Overall, there was an increase in IRDA rates from 2010 to 2019 (right).
fpsyt-11-00245-g003.jpg
PMC7242611_01_fpsyt-11-00245-g003.jpg
f3
Overall, there was an increase in IRDA rates (Figure 3 and Table 1).
Comparison between initial (2010) and follow-up (2019) neuropsychological findings. The findings predominantly improved, but remain mainly still below average.
fpsyt-11-00245-g004.jpg
PMC7242611_01_fpsyt-11-00245-g004.jpg
f4
Compared with the initial neuropsychological testing, the authors detected improved attentional performance at follow-up testing using the Test for Attentional Performance (TAP) battery (Version 2.3.1; Figure 4).